Last reviewed · How we verify
AFP Specific T Cell Receptor T Cells
Specific T Cell Receptor T Cells target the AFP antigen
Specific T Cell Receptor T Cells target the AFP antigen Used for Treatment of AFP-positive cancers.
At a glance
| Generic name | AFP Specific T Cell Receptor T Cells |
|---|---|
| Sponsor | Shanghai Ruiliyuan Biotechnology Co., Ltd. |
| Drug class | CAR-T cell therapy |
| Target | AFP antigen |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 1 |
Mechanism of action
AFP Specific T Cell Receptor T Cells are a type of immunotherapy that uses genetically modified T cells to recognize and attack cancer cells expressing the alpha-fetoprotein (AFP) antigen.
Approved indications
- Treatment of AFP-positive cancers
Common side effects
- Cytokine release syndrome
- Neutropenia
- Anemia
Key clinical trials
- Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2) (PHASE1, PHASE2)
- HRYZ-T102 TCR-T Cell for AFP Positive Advanced HCC and Other Solid Tumors (PHASE1)
- AFPᶜ³³²T in Advanced HCC (PHASE1)
- AFP Specific T Cell Receptor Transduced T Cells Injection(C-TCR055) in Unresectable Hepatocellular Carcinoma (PHASE1)
- AFP Specific T Cell Receptor Transduced T Cells Injection(C-TCR055) in Unresectable Hepatocellular Carcinoma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: